A general strategy towards personalized nanovaccines based on fluoropolymers for post-surgical cancer immunotherapy

  • Nat Nanotechnol. 2020 Dec;15(12):1043-1052. doi: 10.1038/s41565-020-00781-4.
Jun Xu  1 ,  Jia Lv  2 ,  Qi Zhuang  1 ,  Zongjin Yang  1 ,  Zhiqin Cao  1 ,  Ligeng Xu  1 ,  Pei Pei  3 ,  Chenya Wang  1 ,  Hanfei Wu  1 ,  Ziliang Dong  1 ,  Yu Chao  1 ,  Chao Wang  1 ,  Kai Yang  3 ,  Rui Peng  4 ,  Yiyun Cheng  5  6 ,  Zhuang Liu  7
Affiliations
  • 1. Institute of Functional Nano & Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-Based Functional Materials and Devices, Soochow University, Suzhou, China.
  • 2. South China Advanced Institute for Soft Matter Science and Technology, South China University of Technology, Guangzhou, China.
  • 3. State Key Laboratory of Radiation Medicine and Protection, School of Radiation Medicine and Protection and School for Radiological and Interdisciplinary Sciences (RAD-X), Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Soochow University, Suzhou, China.
  • 4. Institute of Functional Nano & Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-Based Functional Materials and Devices, Soochow University, Suzhou, China. [email protected].
  • 5. South China Advanced Institute for Soft Matter Science and Technology, South China University of Technology, Guangzhou, China. [email protected].
  • 6. Shanghai Key Laboratory of Regulatory Biology, School of Life Sciences, East China Normal University, Shanghai, China. [email protected].
  • 7. Institute of Functional Nano & Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-Based Functional Materials and Devices, Soochow University, Suzhou, China. [email protected].
PMID: 33139933 DOI: 10.1038/s41565-020-00781-4
Abstract

Cancer metastases and recurrence after surgical resection remain an important cause of treatment failure. Here we demonstrate a general strategy to fabricate personalized nanovaccines based on a cationic fluoropolymer for post-surgical Cancer Immunotherapy. Nanoparticles formed by mixing the fluoropolymer with a model antigen ovalbumin, induce dendritic cell maturation via the Toll-like Receptor 4 (TLR4)-mediated signalling pathway, and promote antigen transportation into the cytosol of dendritic cells, which leads to an effective antigen cross-presentation. Such a nanovaccine inhibits established ovalbumin-expressing B16-OVA melanoma. More importantly, a mix of the fluoropolymer with cell membranes from resected autologous primary tumours synergizes with checkpoint blockade therapy to inhibit post-surgical tumour recurrence and metastases in two subcutaneous tumour models and an orthotopic breast Cancer tumour. Furthermore, in the orthotopic tumour model, we observed a strong immune memory against tumour rechallenge. Our work offers a simple and general strategy for the preparation of personalized Cancer vaccines to prevent post-operative Cancer recurrence and metastasis.

Products